Spectronaut® 18 makes DIA proteomics projects more efficient and scalable than ever for all mass spectrometry instrument typesNovel research with TrueDiscovery and TrueTarget demonstrates the unique capabilities
Investegate announcements from Biognosys AG, Biognosys Presenting Novel Cancer Research on its Proteomics Platforms and Advancing Data Analysis with the Launch of Proteoverse™ at the AACR Annual Meeting 2023
In collaboration with prominent biopharma companies and academic institutions, Biognosys will demonstrate the technological advances and versatility of the TrueDiscovery, TrueTarget, and TrueSignature
Highlights include the launch of Spectronaut 16, which has undergone one of its most transformative upgrades to date, and innovations to Biognosys' proprietary TrueTarget and TrueDiscovery platforms
Data from Biognosys and its collaborators demonstrate the technological advances and utility of their proteomics platforms in oncology R&D and clinical settings Biognosys, a leader in next-generation